Recruiting
HER2 positive biliary tract cancer
RecruitingStudy of Trastuzumab Deruxtecan and Rilvegostomig for Patients with Advanced HER2-positive Biliary Tract Cancer
Registered drugNo placebo
Study of Trastuzumab Deruxtecan and Rilvegostomig for Patients with Advanced HER2-positive Biliary Tract Cancer
Registered drugNo placebo
- Disease:HER2 positive biliary tract cancer
- Substances:CisplatinDurvalumab+5
Countries:
Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Cisplatin
- Sponsor:AstraZeneca AB



